ICU Medical, Inc. (NASDAQ:ICUI) Receives $175.67 Average PT from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received an average rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $175.6667.

A number of research analysts have weighed in on ICUI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. Piper Sandler lifted their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. KeyCorp increased their target price on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Insiders Place Their Bets

In related news, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the transaction, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in ICU Medical by 80.1% in the 1st quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier’s stock valued at $28,303,000 after acquiring an additional 90,674 shares in the last quarter. Nuveen LLC bought a new stake in shares of ICU Medical during the first quarter valued at approximately $10,827,000. Raymond James Financial Inc. raised its stake in shares of ICU Medical by 7.5% in the first quarter. Raymond James Financial Inc. now owns 69,297 shares of the medical instruments supplier’s stock valued at $9,623,000 after purchasing an additional 4,833 shares in the last quarter. Martingale Asset Management L P lifted its position in ICU Medical by 28.3% in the first quarter. Martingale Asset Management L P now owns 21,561 shares of the medical instruments supplier’s stock worth $2,994,000 after purchasing an additional 4,761 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in ICU Medical by 18.5% during the first quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock worth $96,326,000 after buying an additional 108,493 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Down 0.7%

Shares of ICU Medical stock opened at $145.15 on Thursday. The stock has a market capitalization of $3.58 billion, a P/E ratio of -468.21 and a beta of 0.82. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $134.85 and a two-hundred day moving average price of $129.88. ICU Medical has a 12-month low of $107.00 and a 12-month high of $175.51.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The company had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The company’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Equities analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.